Nomination Committee appointed for the Annual General Meeting 2024
The Nomination Committee for the Annual General Meeting of Bactiguard Holding AB (publ), to be held on Tuesday May 14, 2024, in Stockholm, has been appointed.
The Nomination Committee for the 2024 Annual General Meeting in Bactiguard Holding AB (publ) will consist of the following members:
Helena Borglund, appointed by TomBact AB
Christian Kinch, appointed by GIDL Invest AB
Jan Ståhlberg, appointed by Jan Ståhlberg
Mats J Andersson, appointed by Nordea Fonder
Jannis Kitsakis, appointed by Fjärde AP Fonden
Since the Chairman of the Board of Directors already has a position related to his ownership, the stipulation that the chairman should be co-opted to the Nomination Committee, but without voting rights until further notice, has no practical significance.
In accordance with the instructions for the Nomination Committee in Bactiguard Holding AB (publ), the Nomination Committee shall consist of five members. The Chairman of the Board of Directors shall contact the largest shareholders of the company, in terms of voting power, pursuant to Euroclear Sweden AB’s print out of the share register on August 31. Each of the largest shareholders shall be offered the opportunity to, within reasonable time, appoint a member.
The Nomination Committee will make proposals to the Annual General Meeting 2024 concerning the election of a chairman for the Annual General Meeting, the chairman and other members of the Board of Directors, as well as auditors. The Nomination Committee will also make proposals regarding remuneration to the Board of Directors, including any separate remuneration for committee work, as well as remuneration to the auditors. Further, the Nomination Committee will make a proposal regarding principles for forming the Nomination Committee for the Annual General Meeting in 2025.
Shareholders who wish to make proposals to the Nomination Committee can do so by writing to the Nomination Committee under the following address:
Nomination Committee
Bactiguard Holding AB (publ)
P O Box 15
S - 146 21 Tullinge
Proposals can also be sent by email to the following address: valberedningen@bactiguard.com
In order for the Nomination Committee to be able to address proposals in a constructive manner, they should have been received by January 15, 2024. The proposals of the Nomination Committee will be presented in the invitation to the Annual General Meeting and on the company’s website.
For further information, please contact:
Carin Jakobson, CFO +46 709 651 665
About Bactiguard
Bactiguard is a global medtech company that develops antibacterial, biocompatible and safe technology and solutions to prevent medical device related infections across five therapeutic areas – orthopedics, urology, intravascular/critical care, dental, and wound care.
Bactiguard’s unique technology is based on a thin noble metal coating that prevents bacterial adhesion and biofilm formation on medical devices. Bactiguard’s infection prevention solutions make a positive impact by decreasing patient suffering, saving lives and unburden healthcare resources. They also fight against antimicrobial resistance, one of the most serious threats to global health and modern medicine.
Bactiguard operates through license partnerships with leading global medtech companies, such as BD and Zimmer Biomet, enabling them to bring medical devices with the company’s unique infection prevention technology to the market. Bactiguard also has a portfolio of wound management products and sutures.
Bactiguard is headquartered in Stockholm and listed on Nasdaq Stockholm.
Read more about Bactiguard: www.bactiguard.com
Follow Bactiguard on LinkedIn